PCI – Medxy AI

Ticagrelor Falls Short: TUXEDO-2 Trial Challenges Antiplatelet Choice in Diabetic Patients With Multivessel Disease

By MedXY 04/13/2026

The TUXEDO-2 trial reveals that ticagrelor did not meet noninferiority criteria compared with prasugrel in diabetic patients with multivessel coronary artery disease undergoing PCI. At 1 year, the primary composite endpoint of death, MI, stroke, or major bleeding occurred in 16.6% vs 14.2% of patients, suggesting prasugrel may offer better outcomes in this high-risk population.

Cardiology news

IVUS Guidance Slashes 1-Year Target Vessel Failure in Complex Bifurcation PCI: Insights from DKCRUSH VIII

By MedXY 03/31/2026

The DKCRUSH VIII trial demonstrates that IVUS-guided PCI for complex coronary bifurcation lesions significantly reduces 1-year target vessel failure compared to angiography guidance, primarily by ensuring adherence to specific optimization criteria during the double kissing crush technique.

Cardiology Clinical Updates news

Percutaneous Coronary Intervention Before TAVR: A Nationwide Synthesis of Clinical Outcomes and Bleeding Risks

By MedXY 02/28/2026

A nationwide Swedish registry analysis demonstrates that routine PCI before TAVR for significant coronary artery disease does not improve survival or reduce urgent revascularization, but significantly increases bleeding risk while reducing future nonurgent procedures.

Cardiology news

Is Prasugrel the New Gold Standard? Ticagrelor Fails Noninferiority in High-Risk Diabetic and STEMI Populations

By MedXY 02/20/2026

Recent data from the TUXEDO-2 and ISAR-REACT 5 trials suggest prasugrel may provide superior outcomes over ticagrelor in high-risk PCI patients, including those with diabetes and STEMI.

Cardiology news

FFR-Guided PCI Demonstrates Decade-Long Superiority Over Medical Therapy in Stable CAD: The FAME 2 Trial

By MedXY 02/04/2026

The 11-year FAME 2 trial results confirm that FFR-guided PCI significantly improves outcomes for stable CAD patients with functionally significant lesions, primarily by reducing urgent revascularizations, reinforcing the importance of physiological assessment in revascularization decisions.

Cardiology news

FFR-Guided PCI Demonstrates Decade-Long Superiority Over Medical Therapy in Stable Coronary Artery Disease

By MedXY 02/04/2026

An 11-year follow-up of the FAME 2 trial reveals that FFR-guided PCI significantly outperforms medical therapy alone in patients with hemodynamically significant stenoses, primarily by reducing urgent revascularizations, with a favorable win ratio of 1.25.

Cardiology Internal Medicine news

Aspirin vs. Clopidogrel Beyond 30 Days Post-PCI: Equivalent Outcomes Regardless of Oral Anticoagulation Status

By MedXY 01/18/2026

A subgroup analysis of the STOPDAPT-3 trial reveals that aspirin and clopidogrel offer similar cardiovascular protection and bleeding safety between 1 month and 1 year post-PCI, regardless of whether patients are also receiving oral anticoagulation.

Cardiology Diabetes & Endocrinology news

Abluminus DES+ Fails to Achieve Non-Inferiority Against XIENCE EES in Patients with Diabetes: Results from the ABILITY Diabetes Global Trial

By MedXY 01/18/2026

The ABILITY Diabetes Global trial demonstrates that the Abluminus DES+ sirolimus-eluting stent failed to meet non-inferiority compared to the XIENCE everolimus-eluting stent in patients with diabetes, showing significantly higher rates of target-lesion failure and revascularization at 12 months.

Cardiology news

Validating the 0.80 FFR Threshold: Long-Term Outcomes from the NOTION-3 Trial in TAVR Patients

By MedXY 01/17/2026

The NOTION-3 trial demonstrates that FFR-guided revascularization significantly reduces cardiovascular risks in TAVR patients with coronary artery disease, validating the 0.80 threshold for clinical decision-making.

Cardiology Internal Medicine news

Moving Beyond the 12-Month Default: Personalized DAPT Duration Proven Superior in the PARTHENOPE Trial

By MedXY 01/17/2026

The PARTHENOPE randomized trial demonstrates that personalizing DAPT duration (3 to 24 months) based on individual risk scores significantly reduces net adverse clinical events compared to standard 12-month therapy, primarily by lowering ischemic risks without increasing bleeding.

Cardiology news

Baseline Risk Does Not Resuscitate PCI Benefit in Ischemic Cardiomyopathy: Lessons from the REVIVED-BCIS2 Sub-analysis

By MedXY 01/03/2026

A prespecified analysis of the REVIVED-BCIS2 trial reveals that baseline risk of death or hospitalization does not modify the effectiveness of PCI in patients with ischemic left ventricular dysfunction, reinforcing the primacy of optimal medical therapy.

Cardiology news

FFR-Guided Revascularization Significantly Reduces 12-Month MACCE in TAVI Patients: The FAITAVI Trial

By MedXY 01/03/2026

The FAITAVI trial demonstrates that physiology-guided PCI using FFR significantly reduces major adverse cardiac events, particularly mortality, compared to angiography-guided PCI in elderly patients undergoing TAVI with intermediate coronary lesions.

Cardiology news

Timing Matters: Platelet Reactivity Predicts Early Events While Clinical Risk Governs Long-Term Outcomes Post-PCI

By MedXY 12/30/2025

Analysis of the PTRG-DES registry shows that platelet reactivity drives early ischemic risk post-PCI, while clinical risk factors (TRS2P) determine long-term prognosis, suggesting a need for temporally tailored secondary prevention strategies.

Cardiology news

Refining Risk: Clinical and Angiographic Predictors of Postprocedural Troponin Elevation in Elective PCI

By MedXY 12/30/2025

A comprehensive analysis of over 10,000 patients identifies key risk factors for post-PCI troponin increase, highlighting the protective role of intravascular imaging and the prognostic impact of different myocardial infarction definitions.

Cardiology news

Early Aspirin Withdrawal After PCI in ACS: Less Bleeding but Not Clearly Safe — Lessons from the NEO-MINDSET Trial

By MedXY 12/06/2025

In patients with acute coronary syndromes treated with PCI, stopping aspirin within 4 days and continuing potent P2Y12 inhibitor monotherapy reduced bleeding but did not meet noninferiority for ischemic events versus 12‑month DAPT; stent thrombosis was numerically higher.

Cardiology news

Stopping Aspirin After 1 Month Post‑PCI in Low‑Risk AMI: P2Y12 Monotherapy Is Noninferior and Bleeding‑Sparing

By MedXY 12/06/2025

In low‑risk AMI patients with early complete revascularization and uneventful 1‑month DAPT, P2Y12‑inhibitor monotherapy was noninferior to continued DAPT for ischemic outcomes and substantially reduced clinically relevant bleeding.

Cardiology news

Early Aspirin Withdrawal after PCI in Low‑Risk MI: P2Y12‑Inhibitor Monotherapy Noninferior and Significantly Less Bleeding

By MedXY 12/06/2025

In low‑risk acute MI patients with early complete revascularization and 1 month of uneventful DAPT, stopping aspirin and continuing P2Y12‑inhibitor monotherapy was noninferior for ischemic outcomes and cut clinically relevant bleeding nearly in half.

Cardiology news

CABG Provides Superior Long-Term Outcomes to PCI in Women with Chronic Severe CAD: Real‑World Ontario Cohort Shows Lower MACCE and Mortality

By MedXY 11/28/2025

In a propensity‑matched Ontario cohort of women with chronic severe coronary artery disease, CABG was associated with lower long‑term MACCE and all‑cause mortality than PCI over a median 5.1 years.

Cardiology Clinical Updates news

Aspirin vs. Clopidogrel Monotherapy Following PCI: Insights from the STOPDAPT-3 1-Year Follow-up

By MedXY 09/22/2025

The STOPDAPT-3 trial compared aspirin and clopidogrel monotherapy after short dual antiplatelet therapy in PCI patients, showing similar cardiovascular and bleeding outcomes at 1 year.

Cardiology Clinical Updates news Specialties

Aspirin-Free Strategy in High Bleeding Risk PCI Patients: Insights from STOPDAPT-3 Subgroup Analysis

By MedXY 09/22/2025

In high bleeding risk patients undergoing PCI, aspirin-free prasugrel monotherapy fails to reduce major bleeding and shows increased myocardial infarction risk in ACS but not non-ACS patients, suggesting selective use post-PCI.